[Form 4] Integra LifeSciences Holdings Insider Trading Activity

Rhea-AI Filing Summary

Chantal Veillon-Berteloot, EVP & CHRO of Integra LifeSciences Holdings Corp (IART), reported two sales of company common stock on 09/01/2025. The filing shows a disposition of 2,139 shares at $15.13, leaving 29,059 shares beneficially owned after that transaction, and a separate disposition of 1,412 shares at $15.13, leaving 27,647 shares beneficially owned after that transaction.

The Form 4 is signed by an attorney-in-fact and includes a Power of Attorney exhibit; it documents insider selling and fulfills disclosure requirements under Section 16.

Positive

• Disclosure compliance: Form 4 filed documenting insider transactions and includes an executed Power of Attorney exhibit
• Clear transaction details: Dates, share amounts, prices, and post-transaction beneficial ownership are provided

Negative

• Insider selling: Reporting person disposed of a total of 3,551 shares on 09/01/2025, which may be viewed negatively by some investors

Insights

Financial Analyst

TL;DR: Insider executed routine stock sales totaling 3,551 shares at $15.13; disclosure filed as required.

The transactions reported are outright dispositions on a single date at the same per-share price, suggesting executed sales rather than option exercises or transfers. The sizes—2,139 and 1,412 shares—are disclosed with resulting beneficial ownership counts. There is no earnings, debt, or other financial data in this filing to change company valuation; this is a compliance disclosure showing insider selling activity.

Corporate Governance Expert

TL;DR: Filing meets Section 16 reporting rules; transaction raises routine insider-selling note but no governance red flags shown.

The Form 4 includes the reporting person's title and address, the sale details, and an executed Power of Attorney signature, indicating procedural compliance. The filing does not show any related-party transactions, 10b5-1 plan indication, or amendments. Based solely on this document, there is no evidence of governance issues beyond disclosure of sales.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Veillon-Berteloot Chantal

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CHRO

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2025		F		2,139	D	$15.13	29,059	D
Common Stock	09/01/2025		F		1,412	D	$15.13	27,647	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Lesha Shinn; Attorney-in-Fact	09/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did IART report on this Form 4?

The Form 4 reports two sales on 09/01/2025: 2,139 shares at $15.13 and 1,412 shares at $15.13 by Chantal Veillon-Berteloot.

Who filed the Form 4 for IART?

The reporting person is Chantal Veillon-Berteloot, listed as EVP & CHRO; the form is signed by an attorney-in-fact on the filing.

How many shares did the reporting person own after the reported transactions?

The filing lists post-transaction beneficial ownership of 29,059 shares and 27,647 shares following the two reported dispositions.

Was the sale executed under a 10b5-1 trading plan according to this Form 4?

The document does not indicate that the transactions were made pursuant to a 10b5-1 plan; no such designation is shown in the provided content.

Does this Form 4 disclose derivative transactions or option exercises?

No. Table II for derivative securities contains no entries in the provided content; only non-derivative common stock dispositions are reported.